In one paragraphArticle in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
15 authors.
Asuka Joy TobuseDivision of Vaccine Science, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.ORCID 0000-0002-2617-7651 Kouji KobiyamaDivision of Vaccine Science, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.ORCID 0000-0002-5846-4807 Jun TsuchidaDivision of Vaccine Science, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Masamitsu N AsakaLaboratory of Immunoregulation and Vaccine Research, Tsukuba Primate Research Center, National Institutes of Biomedical Innovation, Health and Nutrition, Tsukuba, Japan.
Daichi UtsumiLaboratory of Immunoregulation and Vaccine Research, Tsukuba Primate Research Center, National Institutes of Biomedical Innovation, Health and Nutrition, Tsukuba, Japan.ORCID 0000-0001-6602-8426 Mariana Silva AlmeidaInternational Vaccine Design Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.ORCID 0000-0001-9694-3721 Yaeko Nakajima-TakagiDivision of Stem Cell and Molecular Medicine, Center for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, University of Tokyo, Tokyo, Japan.ORCID 0000-0002-2341-2409 Motohiko OshimaDivision of Stem Cell and Molecular Medicine, Center for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, University of Tokyo, Tokyo, Japan.ORCID 0000-0001-6991-815X Tomoya HayashiDivision of Vaccine Science, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.ORCID 0000-0003-3189-6463 Burcu TemizozDivision of Vaccine Science, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.ORCID 0000-0002-5189-3529 Etsushi KurodaDepartment of Immunology, Hyogo Medical University School of Medicine, Nishinomiya, Hyogo, Japan.ORCID 0000-0002-7198-2190 Cevayir CobanDepartment of Computational Biology and Medical Science, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan.ORCID 0000-0002-4467-7799 Yasuhiro YasutomiLaboratory of Immunoregulation and Vaccine Research, Tsukuba Primate Research Center, National Institutes of Biomedical Innovation, Health and Nutrition, Tsukuba, Japan.ORCID 0000-0001-8252-1448 Atsushi IwamaDepartment of Computational Biology and Medical Science, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan.ORCID 0000-0001-9410-8992 Ken J IshiiDivision of Vaccine Science, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.ORCID 0000-0002-6728-3872 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
Rapid development of host immunity is critical during the emergence of viral outbreaks when vaccines are not yet available. Here, we demonstrate that CpG oligodeoxynucleotide-schizophyllan complex (K3-SPG) induces antigen-independent, long-term protection against lethal respiratory virus infection. A single intranasal administration successfully enhanced host resistance to infection for as long as 100 days posttreatment. Mechanistically, we observed a lung-restricted biphasic innate activation of macrophages and innate lymphoid cells. Early protection was mediated by CD11b
Indexed as
MacrophagesRespiratory Tract InfectionsToll-Like Receptor 9AnimalsImmunity, InnateLigandsLungMiceOligodeoxyribonucleotidesToll-Like Receptor AgonistsTumor Necrosis Factor-alphaCPG-oligonucleotideLigandsOligodeoxyribonucleotidesTlr9 protein, mouseToll-Like Receptor 9Toll-Like Receptor AgonistsTumor Necrosis Factor-alpha
Identifiers
PMID42853919
PMCPMC13651865
What OpenQuestion holds
Textmetadata
Read underepoch 390